The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway - Meng, Z; Liu, X; Li, T (Int Immunopharmacol, 2021)